Caladrius Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Caladrius Biosciences to Host Fourth Quarter and Full Year 2020 Financial Results Conference .
Caladrius Biosciences, Inc.February 18, 2021 GMT
BASKING RIDGE, N.J., Feb. 18, 2021 (GLOBE NEWSWIRE) Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that the Company will report its financial results for the three and twelve months ended December 31, 2020 on Thursday, February 25, 2021 at 4:30 p.m. Eastern Time.
Live Conference Call and Webcast Details:
U.S. Toll-Free: 866-595-8403
MeiraGTx Announces AAV-CNGA3 Granted Fast Track Designation by U.S. FDA for Treatment of Achromatopsia
LONDON and NEW YORK, Jan. 26, 2021 (GLOBE NEWSWIRE) MeiraGTx Holdings Plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its AAV-CNGA3 gene therapy product candidate for the treatment of achromatopsia (ACHM) caused by mutations in the
CNGA3 gene.
ACHM is an inherited retinal disease that severely limits a person s sight by preventing cone photoreceptors in the eye from functioning. Individuals with ACHM are often legally blind from birth and have extremely debilitating sensitivity to light. AAV-CNGA3 is an investigational gene therapy treatment designed to restore cone function, delivered to the cone receptors at the back of the eye via subretinal injection.
Share:
LONDON and NEW YORK, Dec. 16, 2020 (GLOBE NEWSWIRE) MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced the Company will host a webcast and conference call to provide an update on the Company s AAV-hAQP1 clinical program for the treatment of radiation-induced xerostomia.
The webcast will include discussion of the first cohort of patients (n=3) treated in the Company s Phase 1 AQUAx clinical trial. Of the three patients treated in Cohort 1, one patient has reached the 12-month assessment and two have passed the six-month assessment. In these patients, the investigational gene therapy AAV-hAQP1 has been well tolerated with no dose limiting toxicity and no serious adverse events reported. Encouraging responses have been seen in both patient-reported measures of xerostomia symptoms and in salivary output in the patients treated in Cohort 1, with complete resolution of symptoms in the patient who has reached th
MeiraGTx To Present Clinical Program Update for AAV-hAQP1 Treatment of Radiation-Induced Xerostomia
Webcast and conference call to take place on December 17, 2020 at 8:00 a.m. ET
LONDON and NEW YORK, Dec. 16, 2020 (GLOBE NEWSWIRE) MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced the Company will host a webcast and conference call to provide an update on the Company’s AAV-hAQP1 clinical program for the treatment of radiation-induced xerostomia.
The webcast will include discussion of the first cohort of patients (n=3) treated in the Company’s Phase 1 AQUAx clinical trial. Of the three patients treated in Cohort 1, one patient has reached the 12-month assessment and two have passed the six-month assessment. In these patients, the investigational gene therapy AAV-hAQP1 has been well tolerated with no dose limiting toxicity and no serious adverse events reported. Encouraging responses have been seen in both p